Clinical Trial Update: Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin [Phase 2]

View source ↗

Summary

Phase 2 clinical study exploring biomarkers to predict oxaliplatin-induced neurotoxicity in colorectal cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Eloxatin (oxaliplatin) (oxaliplatin)

Snippet

Sponsor: Institut Cancerologie de l'Ouest | Conditions: Chemotherapeutic Agent Toxicity, Colorectal Cancer | Phase 2 | Status: UNKNOWN